These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32317723)

  • 1. Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients.
    Troiani T; Giunta EF; Tufano M; Vigorito V; Arrigo P; Argenziano G; Ciardiello F; Romano MF; Romano S
    Br J Cancer; 2020 Jun; 122(12):1782-1790. PubMed ID: 32317723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy.
    Romano S; Simeone E; D'Angelillo A; D'Arrigo P; Russo M; Capasso M; Lasorsa VA; Zambrano N; Ascierto PA; Romano MF
    Cancer Immunol Immunother; 2017 Sep; 66(9):1143-1151. PubMed ID: 28434031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulatory pathways regulate expression of a spliced FKBP51 isoform in lymphocytes of melanoma patients.
    Romano S; D'Angelillo A; Staibano S; Simeone E; D'Arrigo P; Ascierto PA; Scalvenzi M; Mascolo M; Ilardi G; Merolla F; Jovarauskaite E; Romano MF
    Pigment Cell Melanoma Res; 2015 Jul; 28(4):442-52. PubMed ID: 25895097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The FKBP51s Splice Isoform Predicts Unfavorable Prognosis in Patients with Glioblastoma.
    Giordano C; Marrone L; Romano S; Della Pepa GM; Donzelli CM; Tufano M; Capasso M; Lasorsa VA; Quintavalle C; Guerri G; Martucci M; Auricchio A; Gessi M; Sala E; Olivi A; Romano MF; Gaudino S
    Cancer Res Commun; 2024 May; 4(5):1296-1306. PubMed ID: 38651817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
    Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
    [No Abstract]   [Full Text] [Related]  

  • 6. Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.
    Serratì S; Guida M; Di Fonte R; De Summa S; Strippoli S; Iacobazzi RM; Quarta A; De Risi I; Guida G; Paradiso A; Porcelli L; Azzariti A
    Mol Cancer; 2022 Jan; 21(1):20. PubMed ID: 35042524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma.
    D'Arrigo P; Russo M; Rea A; Tufano M; Guadagno E; Del Basso De Caro ML; Pacelli R; Hausch F; Staibano S; Ilardi G; Parisi S; Romano MF; Romano S
    Oncotarget; 2017 Sep; 8(40):68291-68304. PubMed ID: 28978117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining Magnetic Resonance Imaging with Systemic Monocyte Evaluation for the Implementation of GBM Management.
    Giordano C; Sabatino G; Romano S; Della Pepa GM; Tufano M; D'Alessandris QG; Cottonaro S; Gessi M; Balducci M; Romano MF; Olivi A; Gaudino S; Colosimo C
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33917598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
    Saito R; Sawada Y; Nakamura M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative splicing of FKBP5 gene exerts control over T lymphocyte expansion.
    Marrone L; D'Agostino M; Cesaro E; di Giacomo V; Urzini S; Romano MF; Romano S
    J Cell Biochem; 2023 Jan; ():. PubMed ID: 36645880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma.
    Serratì S; Di Fonte R; Porcelli L; De Summa S; De Risi I; Fucci L; Ruggieri E; Marvulli TM; Strippoli S; Fasano R; Rafaschieri T; Guida G; Guida M; Azzariti A
    J Exp Clin Cancer Res; 2023 Sep; 42(1):251. PubMed ID: 37759291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.
    Kasanen H; Hernberg M; Mäkelä S; Brück O; Juteau S; Kohtamäki L; Ilander M; Mustjoki S; Kreutzman A
    Cancer Immunol Immunother; 2020 May; 69(5):717-730. PubMed ID: 32036449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
    Twyman-Saint Victor C; Rech AJ; Maity A; Rengan R; Pauken KE; Stelekati E; Benci JL; Xu B; Dada H; Odorizzi PM; Herati RS; Mansfield KD; Patsch D; Amaravadi RK; Schuchter LM; Ishwaran H; Mick R; Pryma DA; Xu X; Feldman MD; Gangadhar TC; Hahn SM; Wherry EJ; Vonderheide RH; Minn AJ
    Nature; 2015 Apr; 520(7547):373-7. PubMed ID: 25754329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
    Ascierto PA; Capone M; Grimaldi AM; Mallardo D; Simeone E; Madonna G; Roder H; Meyer K; Asmellash S; Oliveira C; Roder J; Grigorieva J
    J Immunother Cancer; 2019 Mar; 7(1):91. PubMed ID: 30925943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
    Zhou J; Mahoney KM; Giobbie-Hurder A; Zhao F; Lee S; Liao X; Rodig S; Li J; Wu X; Butterfield LH; Piesche M; Manos MP; Eastman LM; Dranoff G; Freeman GJ; Hodi FS
    Cancer Immunol Res; 2017 Jun; 5(6):480-492. PubMed ID: 28522460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Brief Communication on Circulating PD-1-positive T-Regulatory Lymphocytes in Melanoma Patients Undergoing Adjuvant Immunotherapy With Nivolumab.
    Gambichler T; Schröter U; Höxtermann S; Susok L; Stockfleth E; Becker JC
    J Immunother; 2019 Sep; 42(7):265-268. PubMed ID: 31145230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted deletion of CD244 on monocytes promotes differentiation into anti-tumorigenic macrophages and potentiates PD-L1 blockade in melanoma.
    Kim J; Kim TJ; Chae S; Ha H; Park Y; Park S; Yoon CJ; Lim SA; Lee H; Kim J; Kim J; Im K; Lee K; Kim J; Kim D; Lee E; Shin MH; Park SI; Rhee I; Jung K; Lee J; Lee KH; Hwang D; Lee KM
    Mol Cancer; 2024 Feb; 23(1):45. PubMed ID: 38424542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 Expression Fluctuates Concurrently with Cyclin D in Glioblastoma Cells.
    Tufano M; D'Arrigo P; D'Agostino M; Giordano C; Marrone L; Cesaro E; Romano MF; Romano S
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood.
    Rad Pour S; Pico de Coaña Y; Demorentin XM; Melief J; Thimma M; Wolodarski M; Gomez-Cabrero D; Hansson J; Kiessling R; Tegner J
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.